No more hormone replacement therapy of long duration: Disadvantages outnumber the advantages;De nadelen overtreffen de voordelen: Geen plaats meer voor langdurige hormoonsubstitutietherapie

Pharmaceutisch Weekblad

Volumn 137, Issue 32, 2002, Pages 1132-1134

  Monster, Taco B M ^a   De Jong Van den Berg, Lolkje T W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTROGEN; GESTAGEN; HORMONE; MEDROXYPROGESTERONE ACETATE;

ARTICLE; CANCER RISK; CARDIOVASCULAR RISK; HORMONE SUBSTITUTION; HUMAN; ISCHEMIC HEART DISEASE; LONG TERM CARE; POSTMENOPAUSE; PRIMARY PREVENTION; RISK ASSESSMENT; SECONDARY PREVENTION; THROMBOEMBOLISM;

EID: 0037047576     PISSN: 00316911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial
2. The protective effects of estrogen on the cardiovascular system
3. Postmenopausal hormone therapy and mortality
4. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease
5. Hormone replacement therapy for secondary prevention of coronary heart disease
6. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The writing group for the PEPI trial
7. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
8. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)
9. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis
10. Informatie vooraf is essentieel. Het gebruik van hormoonsubstitutietherapie bij vrouwen
11. Use of hormone replacement therapy by postmenopausal women in the United States